Beijing Inno Medicine Co., Ltd.
Clinical trials sponsored by Beijing Inno Medicine Co., Ltd., explained in plain language.
-
New drug YN001 aims to shrink artery plaque in heart disease trial
Disease control Not yet recruitingThis study tests a drug called YN001 in 456 adults with coronary atherosclerosis (plaque buildup in heart arteries). Participants receive weekly injections of YN001 or a placebo for 13 weeks. The main goal is to see if YN001 reduces plaque volume in the arteries, as measured by a…
Phase: PHASE2 • Sponsor: Beijing Inno Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug aims to tackle two conditions at once: heart disease and erectile dysfunction
Disease control Not yet recruitingThis study tests a new drug called YN001 in 40 people who have both atherosclerotic cardiovascular disease (hardening of the arteries) and erectile dysfunction. The trial is double-blind and placebo-controlled, meaning neither patients nor doctors know who gets the real drug. The…
Phase: PHASE2 • Sponsor: Beijing Inno Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental heart drug combo begins first human safety tests
Knowledge-focused Not yet recruitingThis early-stage trial will test the safety of combining an experimental drug called YN001 with the statin rosuvastatin in 24 healthy Chinese adults aged 18 to 55. Participants will receive YN001 by infusion and rosuvastatin tablets over several weeks. The main goal is to see if …
Phase: PHASE1 • Sponsor: Beijing Inno Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC